Back to top
more

Cencora, Inc. (COR)

(Delayed Data from NYSE)

$237.43 USD

237.43
1,209,653

+1.79 (0.76%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $237.58 +0.15 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (169 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Insulet (PODD) Q4 Earnings, Revenues Top Mark, Margins Expand

by Zacks Equity Research

In the fourth quarter, Insulet (PODD) achieves the milestone of 425,000 estimated active global customers using Omnipod products.

Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down

by Zacks Equity Research

Myriad Genetics (MYGN) registers a strong testing volume improvement across all its businesses in the fourth quarter of 2023.

Alcon (ALC) Q4 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

Alcon (ALC) delivers impressive performance across its franchises in the fourth quarter of 2023.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on continuous recovery of healthcare procedures and upbeat 2024 guidance.

Quest Diagnostics' (DGX) New Pact to Reduce Food Insecurity

by Zacks Equity Research

Quest Diagnostics' (DGX) recent collaboration aims to advance food access and healthy eating habits for underserved communities.

GE HealthCare (GEHC), Biofourmis Partner to Boost At-Home Care

by Zacks Equity Research

GE HealthCare (GEHC) collaborates with Biofourmis to facilitate the patient's journey throughout the healthcare system and make the transition from hospital to home care easier.

Humana (HUM) Collaborates With Veda to Enhance Efficiency

by Zacks Equity Research

Humana (HUM) partners with Veda to enhance the quality of provider directories.

Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Henry Schein (HSIC) Q4 Earnings Miss, Operating Margin Down

by Zacks Equity Research

Henry Schein (HSIC) posts lower-than-expected earnings and revenues in the fourth quarter of 2023.

Here's Why You Should Buy Edward Lifesciences (EW) Stock Now

by Zacks Equity Research

Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.

Penumbra (PEN) Q4 Earnings Top Estimates, Margins Increase

by Zacks Equity Research

Penumbra's (PEN) Q4 revenues register year-over-year growth driven by robust U.S. thrombectomy sales.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Philips' (PHG) New Innovation to Boost Radiation-Free Imaging

by Zacks Equity Research

Philips (PHG) announces its latest LumiGuide imaging technology, which is likely to pave the way for new radiation-free procedures. It will prove beneficial for complex aortic surgeries.

Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ONEV

HCA Healthcare (HCA) Drives Efficiency With New Outpatient Model

by Zacks Equity Research

HCA Healthcare's (HCA) Sarah Cannon Cancer Institute adopts a new outpatient model for CAR T-cell therapy patients.

Amedisys' (AMED) Q4 Earnings Miss Estimates, Margins Up

by Zacks Equity Research

The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q4 performance.

BD (BDX), Camtech Health Unite to Aid Cervical Cancer Screening

by Zacks Equity Research

BD (BDX) collaborates with Camtech Health to improve the rate of cervical cancer screening in Singapore by offering women an option to self-collect samples in the privacy of their own homes.

Lantheus (LNTH) Q4 Earnings Surpass Estimates, Gross Margin Up

by Zacks Equity Research

Lantheus' (LNTH) robust segmental revenues drive its fourth-quarter performance.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio for Now

by Zacks Equity Research

Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.

Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Falls

by Zacks Equity Research

Teleflex (TFX) surpasses earnings and revenue estimates in the fourth quarter of 2023.

Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands

by Zacks Equity Research

Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.

ICON (ICLR) Q4 Earnings Surpass Estimates, Margins Expand

by Zacks Equity Research

ICON's (ICLR) solid performance in the fourth quarter reflects continued market leadership across customer segments it serves.

Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status

by Zacks Equity Research

Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.

Nevro's (NVRO) Q4 Earnings and Sales Top Estimates, Margins Up

by Zacks Equity Research

Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.